- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
DBV Technologies ADR (DBVT)
DBV Technologies ADR stock price live, this page displays NASDAQ DBVT stock exchange data. View the DBVT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the DBV Technologies ADR real time stock price chart below.
What Is the DBV Technologies ADR Stock Price Today?
The DBV Technologies ADR stock price today is 9.100.
What Is the Stock Symbol for DBV Technologies ADR?
The stock ticker symbol for DBV Technologies ADR is DBVT.
Is DBVT the Same as $DBVT?
$DBVT is a common way to refer to the DBV Technologies ADR ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does DBV Technologies ADR Trade On?
DBV Technologies ADR is listed and trades on the NASDAQ stock exchange.
Is DBV Technologies ADR a Good Stock to Buy?
Determining whether DBV Technologies ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current DBV Technologies ADR share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DBVT quote. (ISIN: US23306J3095)
What Is the DBV Technologies ADR Stock Price Today?
The DBV Technologies ADR stock price today is 9.100.
What Is the Stock Symbol for DBV Technologies ADR?
The stock ticker symbol for DBV Technologies ADR is DBVT.
Is DBVT the Same as $DBVT?
$DBVT is a common way to refer to the DBV Technologies ADR ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does DBV Technologies ADR Trade On?
DBV Technologies ADR is listed and trades on the NASDAQ stock exchange.
Is DBV Technologies ADR a Good Stock to Buy?
Determining whether DBV Technologies ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current DBV Technologies ADR share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DBVT quote. (ISIN: US23306J3095)
9.100
-0.390(-4.11%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.050
9.610
52 wk Range
8.630
26.185
DBVT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.0509.610
52 wk Range
8.63026.185
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DBVT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
37.245
Upside
+309.29%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Why is DBV Technologies stock sliding today?- Investing.com
DBV Technologies receives Investment Bank Analyst Rating Update- Investing.com
Pro
- DBV Technologies receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
6 Buy
0 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 37.245
(+309.29% Upside)
DBV Technologies ADR SWOT Analysis
Analyst Optimism | Discover why analysts set price targets ranging from $7.39 to $21.15, reflecting confidence in DBV's pipeline and market potential |
Financial Crossroads | Delve into DBV's financial position, including its $128 million cash reserves and potential $180 million warrant exercise, as it approaches critical milestones |
Market Opportunity | Explore the vast potential of the pediatric peanut allergy market, with projected peak sales exceeding $2 billion for Viaskin Peanut |
Peanut Allergy Pionee | DBV Technologies leads innovation in food allergy treatment with Viaskin Peanut, a non-invasive epicutaneous immunotherapy showing promise in clinical trials |
DBV Technologies ADR Earnings Call Summary for Q3/2026
- DBV completed BLA submission for VIASKIN Peanut patch (ages 4-7) in Q3; expects priority review with 6-month timeline and toddler filing in 2027.
- Cash position reached $165.7M including $50M from RA Capital ADS sale; runway extended into Q3 2027 amid rising commercial preparation costs.
- Operating expenses surged 53.7% to $164.4M year-over-year; sales/marketing spending jumped 726% to $15.7M as company builds launch infrastructure.
- Manufacturing partner Fareva Amboise addressing FDA warning letter; company targets February 2027 for pre-approval inspection readiness with comfortable timing buffer.
- Shares rose 6.07% to $10.74 on BLA progress; management building 50-70 person sales force but declined to provide first-year revenue guidance ahead of launch.
Last Updated: 10/28/2026, 05:49 PM
Read Full TranscriptEarnings
Latest Release
Oct 28, 2026
EPS / Forecast
-0.14 / --
Revenue / Forecast
1.6M / --
Compare DBVT to Peers and Sector
Metrics to compare | DBVT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDBVTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.8x | 14.7x | −0.3x | |
PEG Ratio | −0.06 | 0.13 | 0.00 | |
Price / Book | 3.9x | 2.5x | 2.6x | |
Price / LTM Sales | 152.6x | 3.6x | 2.8x | |
Upside (Analyst Target) | 291.9% | 40.7% | 66.4% | |
Fair Value Upside | Unlock | 20.1% | 9.0% | Unlock |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the DBV Technologies ADR (DBVT) Stock Price Today?
The DBV Technologies ADR stock price today is 9.100 USD.
What Stock Exchange Does DBV Technologies ADR Trade On?
DBV Technologies ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for DBV Technologies ADR?
The stock symbol for DBV Technologies ADR is "DBVT."
What Is the DBV Technologies ADR Market Cap?
As of today, DBV Technologies ADR market cap is 598.190M USD.
What Is DBV Technologies ADR's Earnings Per Share (TTM)?
The DBV Technologies ADR EPS (TTM) is -0.56.
From a Technical Analysis Perspective, Is DBVT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has DBV Technologies ADR Stock Split?
DBV Technologies ADR has split 2 times.
How Many Employees Does DBV Technologies ADR Have?
DBV Technologies ADR has 170 employees.
What is the current trading status of DBV Technologies ADR (DBVT)?
As of Nov 02, 2026, DBV Technologies ADR (DBVT) is trading at a price of 9.100 USD, with a previous close of 9.490 USD. The stock has fluctuated within a day range of 9.050 USD to 9.610 USD, while its 52-week range spans from 8.630 USD to 26.185 USD.
What Is DBV Technologies ADR (DBVT) Price Target According to Analysts?
The average 12-month price target for DBV Technologies ADR is 37.245 USD, with a high estimate of 48.08096623 USD and a low estimate of 5.68552896 USD. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +309.29% Upside potential.
What Is the DBVT Premarket Price?
DBVT's last pre-market stock price is 9.530 USD. The pre-market share volume is 6,160.000, and the stock has decreased by 0.040, or 0.420%.
What Is the DBVT After Hours Price?
DBVT's last after hours stock price is 9.280 USD, the stock has decreased by -0.210, or -2.210%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.